Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 13/20 | 0.50 |
| ▸ | PPARD | Q03181 | 9/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 8/20 | 0.44 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4575310 | 0.87 | PPARA (0.50) | PPARAPPARDABCB11CYP1A2CYP3A4 | |
| SCHEMBL7977777 | 0.84 | PPARA (0.68) | PPARAPPARDABCB11CYP1A2CYP3A4 | |
| SCHEMBL16839699 | 0.81 | KCNQ2 (0.49) | PPARAPPARDPPARGEPHX2KCNQ3 | |
| SCHEMBL21991459 | 0.81 | PPARA (0.62) | PPARAPPARDABCB11CYP1A2CYP3A4 | |
| SCHEMBL3943535 | 0.81 | PPARA (0.62) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL21991824 | 0.80 | MAOB (0.59) | PPARAPPARDABCB11CYP1A2CYP3A4 | |
| SCHEMBL16838978 | 0.80 | EPHX2 (0.49) | PPARAPPARDCYP3A4PPARGEPHX2 | |
| Hydrochloric Acid SCHEMBL11448538 | 0.80 | PPARA (0.61) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL1549422 | 0.79 | PPARA (0.64) | PPARAPPARDABCB11CYP1A2CYP3A4 | |
| SCHEMBL5648539 | 0.78 | PPARA (0.48) | PPARAPPARDPPARGFBP1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-20050137212-A1 | Hppars activators | SMITHKLINE BEECHAM CORPORATION | 2005-06-23 | — | — | US | disclosed |
| EP-1480957-A1 | HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003074495-A1 | HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137212-A1 | Hppars activators | PPARG, PPARA, PPARD | PPARA 2/4885PPARD 3/4885ABCB11 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.